# A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Source: https://onco.cc/trials/nct05133882/  
OnCo record `nct05133882` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.

## Summary

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT05133882 by Sunshine Lake Pharma Co., Ltd., with 133 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Clifutinib Besylate.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05133882
- Phase: 1/2
- Setting: A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia
- Sponsor: Sunshine Lake Pharma Co., Ltd.
- Enrolled: 133

## Sources

- ClinicalTrials.gov NCT05133882: https://clinicaltrials.gov/study/NCT05133882

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Clifutinib](https://onco.cc/drugs/clifutinib/)
- companies: [Sunshine Lake Pharma (HEC)](https://onco.cc/companies/sunshine-lake-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05133882.json